Segment and Geographic Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting

The table below is a summary of the segment profit or loss, including significant segment expenses:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
	(amounts in thousands)
Revenue:
Molecular profiling services	$	207,587	$	93,803	$	484,593	$	254,692
Pharma research and development services	9,246		7,817		34,554		27,653
Revenue	216,833		101,620		519,147		282,345
Less:
Cost of services - Molecular profiling services	66,980		54,810		193,195		167,134
Cost of services - Pharma research and development services	2,347		2,398		7,698		7,130
Selling and marketing expense	41,267		36,758		123,355		115,077
General and administrative expense	51,973		40,852		168,458		126,273
Research and development expense	21,624		27,644		69,739		86,807
Total costs and operating expenses	184,191		162,462		562,445		502,421
Income (Loss) from operations	32,642		(60,842)		(43,298)		(220,076)
Interest income	7,360		1,744		9,482		6,152
Interest expense	(13,507)		(13,799)		(45,497)		(36,763)
Changes in fair value of financial instruments	(2,081)		5,131		(52,285)		6,067
Other income (expense), net	(89)		37		(18,447)		(323)
Segment and consolidated net income (loss)	$	24,325	$	(67,729)	$	(150,045)	$	(244,943)

Schedule of Revenue by Geographic Areas

The following table sets forth the Company’s revenue by geographic areas based on the customer’s location:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
	(amounts in thousands)
United States	$	213,550	$	99,403	$	510,161	$	275,213
International	3,283		2,217		8,986		7,132
Total revenue	$	216,833	$	101,620	$	519,147	$	282,345